{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:45:45Z","timestamp":1790779545691,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2017-85602-R"],"award-info":[{"award-number":["SAF2017-85602-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["FQM-7316"],"award-info":[{"award-number":["FQM-7316"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejmech.2021.113655","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T03:18:45Z","timestamp":1623986325000},"page":"113655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Silyl resveratrol derivatives as potential therapeutic agents for neurodegenerative and neurological diseases"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9327-6182","authenticated-orcid":false,"given":"Efres","family":"Belmonte-Reche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Pe\u00f1alver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-4734","authenticated-orcid":false,"given":"Marta","family":"Caro-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Mateos-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Ad\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gonz\u00e1lez-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-405X","authenticated-orcid":false,"given":"Juan Carlos","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejmech.2021.113655_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0024-3205(99)00410-5","article-title":"Minireview: biological effects of resveratrol","volume":"66","author":"Fr\u00e9mont","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2021.113655_bib2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/BF00029856","article-title":"Cloning and molecular analysis of structural genes involved in flavonoid and stilbene biosynthesis in grape (Vitis vinifera L.)","volume":"24","author":"Sparvoli","year":"1994","journal-title":"Plant Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113655_bib3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.275.5297.218","article-title":"Cancer chemopreventive activity of resveratrol, a natural product derived from grapes","volume":"275","author":"Jang","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113655_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24244506","article-title":"The potential use of resveratrol for cancer prevention","volume":"24","author":"Vervandier-Fasseur","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113655_bib5","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/med.21565","article-title":"Health benefits of resveratrol: evidence from clinical studies","volume":"39","author":"Singh","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.113655_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1527-3466.2004.tb00139.x","article-title":"Cardiovascular protective effects of resveratrol","volume":"22","author":"Bradamante","year":"2004","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.ejmech.2021.113655_bib7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1089\/jmf.2007.0091","article-title":"Beneficial effects of resveratrol on atherosclerosis","volume":"11","author":"Fan","year":"2008","journal-title":"J.\u00a0Med. Food"},{"key":"10.1016\/j.ejmech.2021.113655_bib8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbadis.2014.10.016","article-title":"Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases","volume":"1852","author":"Zordoky","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2021.113655_bib9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12013-015-0612-x","article-title":"Cardioprotection by phytochemicals via antiplatelet effects and metabolism modulations","volume":"73","author":"Zhang","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2021.113655_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neuint.2008.10.008","article-title":"Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease","volume":"54","author":"Karuppagounder","year":"2009","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2021.113655_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuint.2015.10.011","article-title":"Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease","volume":"95","author":"Venigalla","year":"2016","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2021.113655_bib12","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease","volume":"85","author":"Turner","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2021.113655_bib13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3233\/JAD-140444","article-title":"Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer's disease","volume":"42","author":"Porquet","year":"2014","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.ejmech.2021.113655_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.expneurol.2010.05.006","article-title":"Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease","volume":"225","author":"Ho","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2021.113655_bib15","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1007\/s12035-016-0048-3","article-title":"Comparative mitochondrial-based protective effects of resveratrol and nicotinamide in Huntington's disease models","volume":"54","author":"Naia","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2021.113655_bib16","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1039\/C8FO00964C","article-title":"Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T \u03b1-synuclein mouse model of Parkinson's disease","volume":"9","author":"Zhang","year":"2018","journal-title":"Food Funct"},{"key":"10.1016\/j.ejmech.2021.113655_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fnagi.2020.00103","article-title":"Resveratrol derivatives as potential treatments for alzheimer's and Parkinson's disease","volume":"12","author":"Arbo","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2021.113655_bib18","first-page":"419","article-title":"Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice","volume":"11","author":"Mancuso","year":"2014","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"10.1016\/j.ejmech.2021.113655_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fneur.2012.00084","article-title":"Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis","volume":"3","author":"Fonseca-Kelly","year":"2012","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejmech.2021.113655_bib20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.ajpath.2013.07.006","article-title":"Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis","volume":"183","author":"Sato","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2021.113655_bib21","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1007\/s12035-016-9891-5","article-title":"Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study","volume":"54","author":"Ghaiad","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2021.113655_bib22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/nyas.12796","article-title":"Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms","volume":"1348","author":"Britton","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2021.113655_bib23","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbadis.2014.09.011","article-title":"Neuroprotective action of resveratrol","volume":"1852","author":"Bastianetto","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2021.113655_bib24","doi-asserted-by":"crossref","first-page":"111675","DOI":"10.1016\/j.ejmech.2019.111675","article-title":"Review about the multi-target profile of resveratrol and its implication in the SGK1 inhibition","volume":"183","author":"Catalogna","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113655_bib25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/mnfr.200500010","article-title":"Metabolism and bioavailability of trans-resveratrol","volume":"49","author":"Wenzel","year":"2005","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejmech.2021.113655_bib26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mnfr.200700290","article-title":"Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C\/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma","volume":"52","author":"Burkon","year":"2008","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejmech.2021.113655_bib27","series-title":"All Further Development of Resveratrol Drug","author":"halts","year":"2010"},{"key":"10.1016\/j.ejmech.2021.113655_bib28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cmdc.201700045","article-title":"Anticancer activity of stilbene-based derivatives","volume":"12","author":"De Filippis","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113655_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2174\/1389557519666190128093840","article-title":"Derivatives and analogues of resveratrol: recent advances in structural modification","volume":"19","author":"Li","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113655_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/nu9111188","article-title":"Therapeutic versatility of resveratrol derivatives","volume":"9","author":"Nawaz","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.ejmech.2021.113655_bib31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/antiox8080244","article-title":"Strategies to improve resveratrol systemic and topical bioavailability: an update","volume":"8","author":"Intagliata","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejmech.2021.113655_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1389200214666131211160005","article-title":"Prodrugs of quercetin and resveratrol: a strategy under development","volume":"15","author":"Biasutto","year":"2014","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.ejmech.2021.113655_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/nyas.13401","article-title":"Resveratrol derivatives as a pharmacological tool","volume":"1403","author":"Biasutto","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2021.113655_bib34","doi-asserted-by":"crossref","first-page":"7365","DOI":"10.1021\/jm1007006","article-title":"Preventive oral treatment with resveratrol pro-prodrugs drastically reduce colon inflammation in rodents","volume":"53","author":"Larrosa","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113655_bib35","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/cbic.201600084","article-title":"Cytotoxic, antiangiogenic and antitelomerase activity of glucosyl- and acyl- resveratrol prodrugs and resveratrol sulfate metabolites","volume":"17","author":"Falomir","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2021.113655_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejmech.2018.01.037","article-title":"Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases","volume":"146","author":"Pe\u00f1alver","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2021.113655_bib37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1359-6446(03)02726-0","article-title":"Chemistry challenges in lead optimization: silicon isosteres in drug discovery","volume":"8","author":"Showell","year":"2003","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.ejmech.2021.113655_bib38","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/jm3010114","article-title":"Organosilicon molecules with medicinal applications","volume":"56","author":"Franz","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2021.113655_bib39","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1021\/acs.jmedchem.7b00718","article-title":"Quest for novel chemical entities through incorporation of silicon in drug scaffolds","volume":"61","author":"Ramesh","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113655_bib40","first-page":"1301","volume":"vol. 8","author":"Zhang","year":"2006"},{"key":"10.1016\/j.ejmech.2021.113655_bib41","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3109\/03639045.2014.958753","article-title":"Pre-formulation studies of resveratrol","volume":"41","author":"Robinson","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejmech.2021.113655_bib42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.freeradbiomed.2018.10.432","article-title":"Resveratrol decreases the expression of genes involved in inflammation through transcriptional regulation","volume":"130","author":"Pinheiro","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2021.113655_bib43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.reprotox.2009.04.013","article-title":"Zebrafish embryos as models for embryotoxic and teratological effects of chemicals","volume":"28","author":"Yang","year":"2009","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.ejmech.2021.113655_bib44","first-page":"256","article-title":"Zebrafish: as an integrative model for twenty-first century toxicity testing, Birth Defects","volume":"93","author":"Sipes","year":"2011","journal-title":"Res C Embryo Today"},{"key":"10.1016\/j.ejmech.2021.113655_bib45","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.trecan.2020.03.012","article-title":"Zebrafish xenografts for drug discovery and personalized medicine","volume":"6","author":"Xiao","year":"2020","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.ejmech.2021.113655_bib46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/17460441.2019.1577815","article-title":"Screening drugs for myocardial disease in\u00a0vivo with zebrafish: an expert update","volume":"14","author":"Zhao","year":"2019","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113655_bib47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ydbio.2019.07.009","article-title":"Zebrafish and medaka as models for biomedical research of bone diseases","volume":"457","author":"Lleras-Forero","year":"2020","journal-title":"Dev. Biol."},{"key":"10.1016\/j.ejmech.2021.113655_bib48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.expneurol.2017.10.004","article-title":"The developing utility of zebrafish models of neurological and neuropsychiatric disorders: a critical review","volume":"299","author":"Fontana","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2021.113655_bib49","series-title":"Zebrafish as an Emerging Model for Bioassay-Guided Natural Product Drug Discovery for Neurological Disorders","first-page":"6","author":"Pitchai","year":"2019"},{"key":"10.1016\/j.ejmech.2021.113655_bib50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1756-6606-2-20","article-title":"Maternal epileptic seizure induced by pentylenetetrazol: apoptotic neurodegeneration and decreased GABAB1 receptor expression in prenatal rat brain","volume":"2","author":"Naseer","year":"2009","journal-title":"Mol. Brain"},{"key":"10.1016\/j.ejmech.2021.113655_bib51","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ilar.48.4.356","article-title":"Animal models of Huntington's disease","volume":"48","author":"Ramaswamy","year":"2007","journal-title":"ILAR J."},{"key":"10.1016\/j.ejmech.2021.113655_bib52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0149-7634(96)00027-9","article-title":"3-Nitropropionic acid animal model and Huntington's disease","volume":"21","author":"Borlongan","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ejmech.2021.113655_bib53","article-title":"Experimental autoimmune encephalomyelitis in the mouse","volume":"88","author":"Miller","year":"2010","journal-title":"Curr. Protoc. Im."},{"key":"10.1016\/j.ejmech.2021.113655_bib54","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jpba.2011.03.029","article-title":"Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum","volume":"55","author":"Sanchez","year":"2011","journal-title":"J.\u00a0Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2021.113655_bib55","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/gutjnl-2012-302152","article-title":"Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis","volume":"62","author":"Anderson","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2021.113655_bib56","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A\u00a0new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113655_bib57","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1111\/j.0953-816X.2004.03372.x","article-title":"Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease","volume":"19","author":"Diguet","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113655_bib58","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0306-4522(02)00205-1","article-title":"Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl\/6 mice: behavioural and histopathological characterisation","volume":"114","author":"Fernagut","year":"2002","journal-title":"Neuroscience"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421005043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421005043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:31:31Z","timestamp":1759329091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421005043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":58,"alternative-id":["S0223523421005043"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113655","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Silyl resveratrol derivatives as potential therapeutic agents for neurodegenerative and neurological diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113655"}}